Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz

Bibliography

• Bartlett JA, Ferrando SJ. Identification and management of neurologic and psychiatric side effects associated with HIV and HAART. Available from: http://www.medscape.com/viewprogram/2960_pnt
   Google Scholar
• Boyle BA, Goldenberg D. Current issues in antiretroviral and psychiatric therapy for HIV-infected patients. AIDS Reader 2000;10:508-13
   PubMedGoogle Scholar
• Sutterlin S, Vogele C, Gauggel S. Neuropsychiatric complications of efavirenz therapy: suggestions for a new research paradigm. J Neuropsychiatry Clin Neurosci 2010;22:361-9
   PubMed Web of Science ®Google Scholar
• Blanch J, Martinez E, Rousaud A, Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr 2001;27:336-43
   PubMed Web of Science ®Google Scholar
• Gutie´rrez-Valencia A, Viciana P, Palacio R. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events, a randomized trial. Ann Intern Med 2009;151:149-56
   PubMed Web of Science ®Google Scholar
• Puzantian T. Central nervous system adverse effects with efavirenz: case Report and Review. Pharmacotherapy 2002;22:930-3
   PubMed Web of Science ®Google Scholar
• Rihs TA, Begley K, Smith DE, Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med 2006;7:544-8
   PubMed Web of Science ®Google Scholar
• Munoz-Moreno JA, Fumaz CR, Ferrer MJ, Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A Neurobehavioral Review. AIDS Rev 2009;11:103-9
   PubMed Web of Science ®Google Scholar
• Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav 2011;15:1803-18
   PubMed Web of Science ®Google Scholar
• Peyriere H, Mauboussin J, Rouanet I, Management of sudden psychiatric disorders related to efavirenz. AIDS 2001;15:1323-4
   PubMed Web of Science ®Google Scholar
• Bernard EJ. Does efavirenz cause depression? Aids treatment update 2006;158:3
   Google Scholar
• Sabato S. Efavirenz-induced catatonia. AIDS 2002;16:1841-2
   PubMed Web of Science ®Google Scholar
• Jurgen von Giesen H, Koller H, de Nocker D. Long-Term Safety and Efficacy of NNRTI within the Central Nervous System. HIV Clin Trials 2003;4:382-90
   PubMed Web of Science ®Google Scholar
• Moreno A, Labelle C, Samet JH. Recurrence of post-traumatic stress disorder symptoms after initiation of antiretrovirals including efavirenz: a report of two cases. HIV Med 2003;4:302-4
   PubMedGoogle Scholar
• Treisman GJ, Kaplin A. Neurologic and psychiatric complications of antiretroviral agents. AIDS 2002;16:1201-15
   PubMed Web of Science ®Google Scholar
• Fumaz CR, Munoz-Moreno JA, Molto J, Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005;38:560-5
   PubMed Web of Science ®Google Scholar
• Raines C, Radcliffe O, Treisman GJ. Neurologic and psychiatric complications of antiretroviral agents. J Assoc Nurses Aids Care 2005;16:35-48
   PubMed Web of Science ®Google Scholar
• Streck EL, Scain G, Rezin GT, Romao PR. Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. Metab Brain Dis 2008;23:485-92
   PubMed Web of Science ®Google Scholar
• Nolan D, Phillips E, Mallal S. Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. Clin Infec Dis 2006;42:408-10
   PubMed Web of Science ®Google Scholar
• Sustiva (efavirenz) Capsules and Tablets. Full prescribing information, bristol-myers squibb company. Princeton; NJ, USA: 2010
   Google Scholar
• Morlese JF, Qazi NA, Gazzard BG, Nelson MR. Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors? AIDS 2002;16:1840-1
   PubMed Web of Science ®Google Scholar
• Turjanski N, Lloyd GG. Psychiatric side-effects of medications: recent developments. Adv Psychiatr Treat 2005;11:58-70
   Google Scholar
• Arendt G, de Nocker D, von Giesen HJ, Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf 2007;6:147-54
   PubMed Web of Science ®Google Scholar
• Everall IP, Drummond S, Catalan J. Guidelines for the prescribing of medication for mental health disorders for people with HIV infection (Draft) (Council Report CR127). London: Royal College of Psychiatrists 2004. Available from: www.rcpsych.ac.uk/publications/cr/council/cr127.doc
   Google Scholar
• Goudie AJ. Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats. J Psychopharmacol March 2007;2:179-90
   Google Scholar
• Tatro DS. editor. Drug Interaction Facts. Wolters Kluwer Health, Inc; St. Louis, MO: 2012
   Google Scholar
• Lexi-Comp, Inc. (Lexi-DrugsTM). Lexi-Comp, Inc.; 2012
   Google Scholar
• Micromedex®. Version 1514 Thomson Reuters (Healthcare) Inc; Greenwood Village, Colo: 2010
   Google Scholar
• Olarte-Sanchez CM, Torres LV, Bod S. A clozapine-like effect of cyproheptadine on progressive ratio schedule performance. J Psychopharmacol 2012;26:857-70
   PubMed Web of Science ®Google Scholar
• Koek W, Jackson A, Colpaert FC. Behavioural pharmacology of antagonists at 5-HT2/5-HT1C receptors. Neurosci Biobehav Rev 1992;16:95-105
   PubMed Web of Science ®Google Scholar
• Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083-152
   PubMed Web of Science ®Google Scholar
• Bourgeois JA, Hales RE, Young JS, The American psychiatric publishing board review guide for psychiatry. American Psychiatric Publishing, Inc, Washington, DC;2009. p. 442
   Google Scholar
• Lee HS, Song DH, Kim JH, Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1995;10:67-72
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Mohammadi MA, Amini-Nooshabadi H, Davari-Ashtiani Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. J Clin Pharm Ther 1999;24:49-52
   PubMed Web of Science ®Google Scholar
• Harsch H H. Cyproheptadine for recurrent nightmares. Am J Psychiatry 1986;143:11
   PubMed Web of Science ®Google Scholar
• Brophy MH. Cyproheptadine for combat nightmares in post-traumatic stress disorder and dream anxiety disorder. Mil Med 1991;156:100-1
   PubMed Web of Science ®Google Scholar
• Rijnders RJ, Laman D M, Van diujn H. Cyproheptadine for posttraumatic nightmares. M J Psychiatry 2000;157:9
   Google Scholar
• Yonker ME. Pharmacologic treatment of migraine. Curr Pain and Headache Rep 2006;10:377-81
   PubMedGoogle Scholar
• Stark RJ, Stark CD. Migraine prophylaxis. Med J Aust 2008;189:283-9
   PubMed Web of Science ®Google Scholar
• Tokunaga S, Takeda Y, Shinomiya K. Effects of some H 1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci 2007;103:201-6
   PubMed Web of Science ®Google Scholar
• Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacolo 2004;14:65-72
   PubMed Web of Science ®Google Scholar
• Gupta S, Popli A, Bathurst E, Efficacy of Cyproheptadine for nightmares associated with posttraumatic stress disorder. Compr Psychiatry 1998;39:160-4
   PubMed Web of Science ®Google Scholar
• Murphy JE. Mianserin in the treatment of depressive illness and anxiety states in general practice. Br J Clin Pharmac 1978;5:81S-5S
   Web of Science ®Google Scholar
• Pangalila-Ratu Langi EA, Jansen AA. Ritanserin in the treatment of generalized anxiety disorders: a placebo-controlled trial. Hum Psychopharmacolo 1988;3:207-12
   Google Scholar
• Greenway SE, Pack AT, Greenway FL. Treatment of depression with cyproheptadine. Pharmacotherapy 1995;15:361-403
   Web of Science ®Google Scholar
• Silver H, Blacker M, Weller MPI, Lerer B. Treatment of chronic schizophrenia with cyproheptadine. Biol Psychiatry 1989;25:502-4
   PubMed Web of Science ®Google Scholar
• Silver H, Blacker M, Weller MPI, Lerer B. Treatment of chronic schizophrenia with cyproheptadine: a double- blind placebo-controlled study. Biol Psychiatry 1991;39:523-5
   Google Scholar
• Chaudhry IB, Soni SD, Hellewell JS, Deakin JF. Antisaccade, executive and clinical measures in schizophrenia are unaffected by acute 5ht2a/2c antagonism using cyproheptadine. Schizophr Res 1996;18:220
   PubMed Web of Science ®Google Scholar
• Chaudhry IB, Soni SD, Hellewell JS, Deakin JF. Effects of the 5HT antagonist cyproheptadine on neuropsychological function in chronic schizophrenia. Schizophr Res 2002;53:17-24
   PubMed Web of Science ®Google Scholar
• Nappi Gi, Sandrini G, Granella F, A new 5-HT2 antagonist (Ritanserin) in the treatment of chronic headache with depression. A double-llind study vs amitriptyline. J Head Face Pain 1990;30:439-44
   PubMed Web of Science ®Google Scholar
• Rao BS, Das DG, Taraknath VR, Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India 2000;48:223-6
   PubMed Web of Science ®Google Scholar
• Polsky B, Kotler D, Steinhart C. HIV-Associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment. AIDS Patient Care STDS 2001;15:411-23
   PubMed Web of Science ®Google Scholar
• Stiel ON, Liddle GW, Lacy WW. Studies of mechanism of cyproheptadine-induced weight gain in human subjects. Metabolism 1970;19:192-200
   PubMedGoogle Scholar
• Comer SD, Haney M, Fischman MW, Foltin RW. Cyproheptadine produced modest increases in total caloric intake by humans. Physiol Behav 1997;62:831-9
   PubMed Web of Science ®Google Scholar
• Homnick DN, Homnick BD, Reeves AJ, Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatr Pulmonol 2004;38:129-34
   PubMed Web of Science ®Google Scholar
• Homnick DN, Marks JH, Hare KL, Bonnema SK. Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatr Pulmonol 2005;40:251-6
   PubMed Web of Science ®Google Scholar
• Epifanio M, Marostica PC, Nejedlo R, A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. J Pediatr (Rio J) 2012;88:155-60
   PubMed Web of Science ®Google Scholar
• Rerksuppaphol S, Rerksuppaphol L. Effect of cyproheptadine on weight gain in malnourished children: a randomized, controlled trial. Asian Biomed 2010;4:977-82
   Web of Science ®Google Scholar